CN109694394B - Preparation method and application of tannin extract in sea buckthorn - Google Patents
Preparation method and application of tannin extract in sea buckthorn Download PDFInfo
- Publication number
- CN109694394B CN109694394B CN201811491836.0A CN201811491836A CN109694394B CN 109694394 B CN109694394 B CN 109694394B CN 201811491836 A CN201811491836 A CN 201811491836A CN 109694394 B CN109694394 B CN 109694394B
- Authority
- CN
- China
- Prior art keywords
- extract
- sea buckthorn
- methanol
- tannin extract
- tannin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 36
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title claims abstract description 25
- 229920001864 tannin Polymers 0.000 title claims abstract description 18
- 239000001648 tannin Substances 0.000 title claims abstract description 18
- 235000018553 tannin Nutrition 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 240000000950 Hippophae rhamnoides Species 0.000 title description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 30
- 241000229143 Hippophae Species 0.000 claims abstract description 23
- 238000004440 column chromatography Methods 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000002953 preparative HPLC Methods 0.000 claims abstract description 4
- 239000000741 silica gel Substances 0.000 claims abstract description 4
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 4
- 238000002791 soaking Methods 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 230000003579 anti-obesity Effects 0.000 abstract description 7
- 208000008589 Obesity Diseases 0.000 abstract description 6
- 235000020824 obesity Nutrition 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 235000003935 Hippophae Nutrition 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 3
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- CSCPPACGZOOCGX-MICDWDOJSA-N 1-deuteriopropan-2-one Chemical compound [2H]CC(C)=O CSCPPACGZOOCGX-MICDWDOJSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域technical field
本发明属于中药提取物领域,涉及一种来源于沙棘的具有抗炎和抗肥胖辅助性治疗提取物,特别是指一种沙棘中鞣质提取物的制备方法及其用途。The invention belongs to the field of traditional Chinese medicine extracts, and relates to an extract derived from sea buckthorn with anti-inflammatory and anti-obesity adjuvant therapy, in particular to a preparation method and use of a tannin extract from sea buckthorn.
背景技术Background technique
肥胖外因以饮食过多而活动过少为主。热量摄入多于热量消耗,使脂肪合成增加是肥胖的物质基础。内因为脂肪代谢紊乱而致肥胖。肥胖患者当使用药物减轻体重后,也需要持续用药保持。但临床上如何更好地应用这类药物仍有待探讨。用药可能产生药物副作用及耐药性,因而选择药物治疗的适应证必须十分慎重,根据患者的个体情况衡量可能得到的益处和潜在的危险作出决定。Obesity is mainly caused by eating too much and too little activity. The calorie intake is more than the calorie consumption, and the increase of fat synthesis is the material basis of obesity. Obesity due to fat metabolism disorder. Obese patients also need to continue medication to maintain their weight after using medication to lose weight. However, how to better apply these drugs in clinical practice remains to be explored. Drug use may cause drug side effects and drug resistance, so the selection of drug treatment indications must be very careful, and the decision should be made based on the patient's individual situation to weigh the possible benefits and potential risks.
因此,传统抗肥胖药物的地位有所降低,目前只是作为短期治疗措施来应用。尽管如此,该类药物在治疗严重肥胖患者时仍然是一种不可或缺的基本药物。因此,寻找毒副作用小的抗肥胖药物对于肥胖的治疗和预防仍然具有重要意义。Therefore, the status of traditional anti-obesity drugs has been reduced, and they are currently only used as short-term treatment measures. Nonetheless, this class of drugs remains an indispensable essential drug in the treatment of severely obese patients. Therefore, the search for anti-obesity drugs with less toxic and side effects is still of great significance for the treatment and prevention of obesity.
我国植被丰富,亟待开发与应用。沙棘(Hippophae rhamnoides L.)为胡颓子科沙棘属的落叶灌木或小乔木,主要分布在丝绸之路沿线国家。我国是世界上沙棘种质资源和蕴藏量最丰富的国家,共有7种7亚种,广泛分布于我国西北、华北、东北、西南等地,其蕴藏量约占世界沙棘资源的90%。my country is rich in vegetation, which needs to be developed and applied urgently. Seabuckthorn (Hippophae rhamnoides L.) is a deciduous shrub or small tree of the genus Seabuckthorn in the family Elaeaceae, mainly distributed in countries along the Silk Road. my country is the country with the most abundant sea buckthorn germplasm resources and reserves in the world. There are 7 species and 7 subspecies, which are widely distributed in Northwest my country, North China, Northeast China, Southwest China and other places. Its reserves account for about 90% of the world's sea buckthorn resources.
发明内容SUMMARY OF THE INVENTION
本发明的目的在于提出一种沙棘中鞣质提取物的制备方法及其用途。The purpose of the present invention is to propose a preparation method and application of tannin extract in sea buckthorn.
为实现上述目的,本发明通过下述技术方案来实现:所述一种沙棘中鞣质提取物在抗肥胖辅助性治疗药物中的用途。In order to achieve the above object, the present invention is achieved through the following technical scheme: the use of the tannin extract from the sea buckthorn in an anti-obesity adjuvant therapeutic drug.
所述沙棘中鞣质提取物具有如式1、式2、式3所示结构的组分:The tannin extract in the sea buckthorn has the components shown in formula 1,
其中R1、R2、R3、R4、R5中的H为氢或没食子酰基。Wherein, H in R1, R2, R3, R4 and R5 is hydrogen or galloyl group.
所述沙棘中鞣质提取物按以下方法制备得到:The tannin extract in the sea buckthorn is prepared by the following method:
(1)将沙棘叶6kg用80%含水醇溶液浸泡提取,滤过合并提取液,减压浓缩得浸膏1.4kg,备用;(1) 6kg of sea buckthorn leaf is soaked and extracted with 80% aqueous alcohol solution, filtered and merged extract, concentrated under reduced pressure to obtain extract 1.4kg, for subsequent use;
(2)将备用浸膏用水分散后,用有机溶剂萃取,减压回收溶剂待用;(2) after the standby extract is dispersed with water, extracted with an organic solvent, and the solvent is recovered under reduced pressure for use;
(3)取经过上述步骤的浸膏,用20%甲醇溶解后,进行Sephadex LH-20柱色谱分离,以甲醇-水(20:80→100:0)溶剂系统梯度洗脱,得到4个部分 Fr.1-4,Fr.4(20g)经过硅胶、MCI CHP-20柱色谱和半制备高效液相色谱分离纯化,得到化合物。(3) Take the extract that has undergone the above steps, dissolve it in 20% methanol, carry out Sephadex LH-20 column chromatography, and elute with methanol-water (20:80→100:0) solvent system gradient to obtain 4 parts Fr.1-4, Fr.4 (20g) were separated and purified by silica gel, MCI CHP-20 column chromatography and semi-preparative high performance liquid chromatography to obtain compounds.
所述含水醇溶液为甲醇,甲醇浸泡反复提取3-4次,提取温度20-70℃。The aqueous alcohol solution is methanol, and the methanol is soaked and extracted repeatedly for 3-4 times, and the extraction temperature is 20-70 DEG C.
所述机溶剂为氯仿、乙酸乙酯、正丁醇。The organic solvent is chloroform, ethyl acetate and n-butanol.
所述机溶剂萃取步骤为用氯仿、乙酸乙酯、正丁醇分别萃取3-4次,萃取温度为18-35℃。The organic solvent extraction step is to extract 3-4 times with chloroform, ethyl acetate and n-butanol respectively, and the extraction temperature is 18-35°C.
本发明所述一种沙棘中鞣质提取物的制备方法及其用途,有益效果在于:中鞣质提取物能够用于肥胖的预防和治疗,本发明通过生物活性测试实验表明,所述沙棘鞣质提取物具有强抗肥胖作用。The preparation method and application of the tannin extract of sea buckthorn according to the present invention has the beneficial effects that the tannin extract can be used for the prevention and treatment of obesity. The extract has a strong anti-obesity effect.
说明书附图Instruction drawings
图1为槲皮素、多数鞣质类化合物对脂肪细胞TG蓄积和分化的抑制率。Figure 1 shows the inhibition rate of quercetin and most tannins on the accumulation and differentiation of TG in adipocytes.
具体实施方式Detailed ways
实施例1Example 1
1、材料:1. Materials:
实验用沙棘叶采于内蒙古,为沙棘Hippophae rhamnoides L.的干燥叶。The sea buckthorn leaves used in the experiment were collected from Inner Mongolia and were dried leaves of Hippophae rhamnoides L..
2、提取与分离:2. Extraction and separation:
沙棘叶6kg用80%甲醇浸泡提取,反复3次,滤过合并提取液,减压浓缩得浸膏1.4kg。浸膏用水分散后,用氯仿、乙酸乙酯、正丁醇分别萃取3次,减压回收溶剂,得相应的提取物,其中乙酸乙酯层和水层分别是60g和933g。取乙酸乙酯部位57g浸膏,20%甲醇溶解后,进行Sephadex LH-20柱色谱分离,以甲醇-水(20:80→100:0)溶剂系统梯度洗脱,得到4个部分Fr.1-4,Fr.4 (20g)经过硅胶、MCI CHP-20柱色谱和半制备高效液相色谱分离纯化,得到化合物。6 kg of sea buckthorn leaves were soaked and extracted with 80% methanol, repeated 3 times, filtered to combine the extracts, and concentrated under reduced pressure to obtain 1.4 kg of extract. After the extract was dispersed with water, it was extracted three times with chloroform, ethyl acetate and n-butanol, respectively, and the solvent was recovered under reduced pressure to obtain the corresponding extract, wherein the ethyl acetate layer and the water layer were 60 g and 933 g respectively. Take 57g of the extract from the ethyl acetate part, dissolve it in 20% methanol, carry out Sephadex LH-20 column chromatography, and elute with methanol-water (20:80→100:0) solvent system gradient to obtain 4 parts Fr.1 -4, Fr.4 (20g) was separated and purified by silica gel, MCI CHP-20 column chromatography and semi-preparative high performance liquid chromatography to obtain the compound.
3、结构鉴定:3. Structure identification:
化合物1:浅褐色粉末,FAB-MS(m/z):787[M-H]-,HR-FAB-MS(m/z):found.787.0993[M-H]-(calcd.787.0992for C34H27O22);1H-NMR(Acetone-d6,600MHz) δ:6.01(1H,d,J=8.3Hz,glu,H-1),4.09(1H,t,J=8.6Hz,H-2),5.70 (1H,t,J=9.6Hz,H-3),5.51(1H,t,J=9.6Hz,H-4),4.41(1H,m, H-5),4.58(1H,dd,J=12.4,1.7Hz,H-6α),4.49(1H,dd,J=12.4, 5.2Hz,H-6β),7.21,7.15,7.10,7.07(各2H,s,galloyl);13C-NMR (Acetone-d6,150MHz)δ:94.8(glu,C-1),71.2(C-2),75.1(C-3),68.9 (C-4),73.0(C-5),62.6(C-6),120.2,121.1,119.4,119.4(C-1,galloyl), 109.6,109.4,109.4(C-2,6),109.3,145.5,145.4,145.4,145.3(C-3, 5),139.2,139.0,138.5,138.5(C-4),166.21,166.2,165.7,165.3(C=O)。Compound 1: light brown powder, FAB-MS(m/z): 787[MH] - , HR-FAB-MS(m/z): found.787.0993[MH] - ( calcd.787.0992for C34H27O 22 ); 1 H-NMR (Acetone-d 6 , 600MHz) δ: 6.01 (1H, d, J=8.3Hz, glu, H-1), 4.09 (1H, t, J=8.6Hz, H-2) ,5.70(1H,t,J=9.6Hz,H-3),5.51(1H,t,J=9.6Hz,H-4),4.41(1H,m,H-5),4.58(1H,dd, J=12.4, 1.7Hz, H-6α), 4.49 (1H, dd, J=12.4, 5.2Hz, H-6β), 7.21, 7.15, 7.10, 7.07 (each 2H, s, galloyl); 13 C-NMR (Acetone-d 6 , 150MHz)δ:94.8(glu,C-1),71.2(C-2),75.1(C-3),68.9(C-4),73.0(C-5),62.6(C -6),120.2,121.1,119.4,119.4(C-1,galloyl), 109.6,109.4,109.4(C-2,6),109.3,145.5,145.4,145.4,145.3(C-3,5),139.2 , 139.0, 138.5, 138.5 (C-4), 166.21, 166.2, 165.7, 165.3 (C=O).
化合物2:浅褐色粉末,FAB-MS(m/z):787[M-H]-,HR-FAB-MS(m/z):found.787.0993[M-H]-(calcd.787.0992for C34H27O22);1H-NMR(Acetone-d6,600MHz) δ:6.19(1H,d,J=8.6Hz,glu,H-1),5.48(1H,t,J=8.6Hz,H-2), 5.69(1H,t,J=8.9Hz,H-3),4.11(1H,m,H-4),4.16(1H,m,H-5),4.62 (1H,dd,J=12.1,1.8Hz,H-6α),4.58(1H,dd,J=12.1,4.7Hz,H-6 β),7.19,7.10,7.09,7.01(各2H,s,galloyl);13C-NMR(Acetone-d6,150 MHz)δ:93.5(glu,C-1),71.8(C-2),75.9(C-3),68.4(C-4),76.1(C-5), 63.7(C-6),121.6,121.4,120.8,120.1(C-1,galloyl),110.3,110.2,110.1, 110.0(C-2,6),146.1,146.1,145.9,145.9(C-3,5),139.7,139.2,139.0, 138.9(C-4),166.6,166.2,165.8,165.0(C=O)。Compound 2: light brown powder, FAB-MS(m/z): 787[MH] - , HR-FAB-MS(m/z): found.787.0993[MH] - ( calcd.787.0992for C34H27O 22 ); 1 H-NMR (Acetone-d 6 , 600MHz) δ: 6.19 (1H, d, J=8.6Hz, glu, H-1), 5.48 (1H, t, J=8.6Hz, H-2) , 5.69(1H,t,J=8.9Hz,H-3),4.11(1H,m,H-4),4.16(1H,m,H-5),4.62(1H,dd,J=12.1,1.8 Hz, H-6α), 4.58 (1H, dd, J=12.1, 4.7Hz, H-6 β), 7.19, 7.10, 7.09, 7.01 (each 2H, s, galloyl); 13 C-NMR (Acetone-d 6,150 MHz)δ: 93.5(glu,C-1), 71.8(C-2), 75.9(C-3), 68.4(C-4), 76.1(C-5), 63.7(C-6) ,121.6,121.4,120.8,120.1(C-1,galloyl),110.3,110.2,110.1, 110.0(C-2,6),146.1,146.1,145.9,145.9(C-3,5),139.7,139.2, 139.0, 138.9 (C-4), 166.6, 166.2, 165.8, 165.0 (C=O).
化合物3:浅褐色粉末FAB-MS(m/z):939[M-H]-,HR-FAB-MS(m/z):found.939.1103[M-H]-(calcd.939.1102for C41H31O26);1H-NMR(Acetone-d6,600 MHz)δ:6.34(1H,d,J=8.5Hz,glu,H-1),5.62(1H,t,J=8.4Hz,H-2), 6.02(1H,t,J=9.5Hz,H-3),5.67(1H,t,J=9.5Hz,H-4),4.58(1H, m,H-5),4.55(1H,dd,J=12.4,1.9Hz,H-6α),4.42(1H,dd,J=12.4, 4.4Hz,H-6β),7.19,7.12,7.06,7.02,6.98(各2H,s,galloyl);13C-NMR(Acetone-d6,150MHz)δ:93.3(glu,C-1),71.8(C-2),73.3(C-3),69.3 (C-4),74.0(C-5),62.8(C-6),121.4,120.7,120.6,120.6,119.9(C-1, galloyl),110.4,110.3,110.2,110.1,110.1(C-2,6),146.1,146.03, 145.98,145.94,145.86(C-3,5),139.8,139.4,139.3,139.2,139.0(C-4), 166.4,165.9,165.7,165.6,165.0(C=O)。Compound 3: light brown powder FAB-MS (m/z): 939 [MH] - , HR-FAB-MS (m/z): found. 939.1103 [MH] - (calcd. 939.1102 for C 41 H 31 O 26 ); 1 H-NMR (Acetone-d 6 , 600 MHz) δ: 6.34 (1H, d, J=8.5Hz, glu, H-1), 5.62 (1H, t, J=8.4Hz, H-2) , 6.02(1H,t,J=9.5Hz,H-3),5.67(1H,t,J=9.5Hz,H-4),4.58(1H,m,H-5),4.55(1H,dd, 13C -NMR (Acetone-d 6 , 150MHz) δ: 93.3 (glu, C-1), 71.8 (C-2), 73.3 (C-3), 69.3 (C-4), 74.0 (C-5), 62.8 (C-6), 121.4, 120.7, 120.6, 120.6, 119.9 (C-1, galloyl), 110.4, 110.3, 110.2, 110.1, 110.1 (C-2, 6), 146.1, 146.03, 145.98, 145.94, 145.86( C-3,5), 139.8, 139.4, 139.3, 139.2, 139.0 (C-4), 166.4, 165.9, 165.7, 165.6, 165.0 (C=O).
4、抗肥胖活性评价:4. Evaluation of anti-obesity activity:
4.1抑制3T3L-1脂肪细胞甘油三酯(TG)蓄积的抗肥胖活性评价:4.1 Evaluation of anti-obesity activity by inhibiting 3T3L-1 adipocyte triglyceride (TG) accumulation:
用含10%新生小牛血清的高糖DMEM培养基,在37℃、5%CO2条件下培养 3T3-L1脂肪细胞,待细胞生长至完全融合后两天(第0天)时,更换成诱导分化培养基(含10%胎牛血清、10μg/mL胰岛素、1.0μM地塞米松、500μM 1-甲基-3-异丁基黄嘌呤)并添加不同浓度的样品培养3天,换用促进分化培养基(含 10%胎牛血清、5μg/mL胰岛素)并添加不同浓度的样品培养3天,换用同样培养基并添加不同浓度的样品培养至第8天。以未加样品的细胞培养液为阴性对照,显微镜下观察,可见该阴性对照细胞体内脂肪滴明显;以槲皮素为阳性对照。 3T3-L1脂肪细胞用PBS(-)清洗后,用含1mM EDTA的25mM Tris-HCl缓冲液收集细胞,超声匀浆,用LabAssayTM Triglyceride试剂盒(WAKO Pure Chemical Industries Ltd.)测定细胞中蓄积的甘油三酯(TG)含量,同时用甘油磷酸脱氢酶(GPDH)试剂盒(TaKaRa BioInc.)测定GPDH活性,分别定量分析脂肪蓄积和分化程度,评价供试品的抗肥胖活性。3T3-L1 adipocytes were cultured in high-glucose DMEM medium containing 10% newborn calf serum at 37°C and 5% CO 2 . Induce differentiation medium (containing 10% fetal bovine serum, 10 μg/mL insulin, 1.0 μM dexamethasone, 500 μM 1-methyl-3-isobutylxanthine) and add different concentrations of samples to culture for 3 days, then switch to promoting Differentiation medium (containing 10% fetal bovine serum, 5 μg/mL insulin) and samples with different concentrations were added for 3 days, and the same medium was changed to the same medium and samples with different concentrations were added for 8 days. Taking the cell culture medium without sample as the negative control, observed under the microscope, it can be seen that the negative control cells have obvious fat droplets in the body; taking quercetin as the positive control. After 3T3-L1 adipocytes were washed with PBS(-), the cells were harvested with 25 mM Tris-HCl buffer containing 1 mM EDTA, homogenized by sonication, and the accumulated glycerol in the cells was determined using the LabAssayTM Triglyceride Kit (WAKO Pure Chemical Industries Ltd.). Triester (TG) content, GPDH activity was measured with glycerol phosphate dehydrogenase (GPDH) kit (TaKaRa BioInc.), respectively, quantitative analysis of fat accumulation and differentiation degree, evaluation of the anti-obesity activity of the test sample.
实验结果如图1显示,在10μM浓度时,阳性对照槲皮素对脂肪细胞TG蓄积和分化的抑制率约为25%,同浓度下的多数鞣质类化合物的抑制率约为 30-40%,普遍较槲皮素抑制作用强。The experimental results are shown in Figure 1. At 10 μM concentration, the inhibition rate of positive control quercetin on adipocyte TG accumulation and differentiation is about 25%, and the inhibition rate of most tannins at the same concentration is about 30-40% , generally stronger than the inhibitory effect of quercetin.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811491836.0A CN109694394B (en) | 2018-12-07 | 2018-12-07 | Preparation method and application of tannin extract in sea buckthorn |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811491836.0A CN109694394B (en) | 2018-12-07 | 2018-12-07 | Preparation method and application of tannin extract in sea buckthorn |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109694394A CN109694394A (en) | 2019-04-30 |
CN109694394B true CN109694394B (en) | 2022-08-09 |
Family
ID=66230366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811491836.0A Active CN109694394B (en) | 2018-12-07 | 2018-12-07 | Preparation method and application of tannin extract in sea buckthorn |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109694394B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1308084A (en) * | 2001-02-13 | 2001-08-15 | 天津市阳成高科技天然制品有限公司 | Resin adsorption process of preparing sea-buckthorn flavone with sea-buckthorn leaf |
CN1504473A (en) * | 2002-12-05 | 2004-06-16 | 河北神兴沙棘研究院 | Resin adsorption process for preparing tannin from sea-buckthorn leaf |
CN1562280A (en) * | 2004-04-01 | 2005-01-12 | 暨南大学 | Application of cocoa extract in preparing medication of preventing and improving fatness and clinical symptom, and foodstuff |
WO2013085338A2 (en) * | 2011-12-07 | 2013-06-13 | 한국생명공학연구원 | Pharmaceutical composition for preventing and treating metabolic diseases, comprising nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract as active ingredients |
-
2018
- 2018-12-07 CN CN201811491836.0A patent/CN109694394B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1308084A (en) * | 2001-02-13 | 2001-08-15 | 天津市阳成高科技天然制品有限公司 | Resin adsorption process of preparing sea-buckthorn flavone with sea-buckthorn leaf |
CN1504473A (en) * | 2002-12-05 | 2004-06-16 | 河北神兴沙棘研究院 | Resin adsorption process for preparing tannin from sea-buckthorn leaf |
CN1562280A (en) * | 2004-04-01 | 2005-01-12 | 暨南大学 | Application of cocoa extract in preparing medication of preventing and improving fatness and clinical symptom, and foodstuff |
WO2013085338A2 (en) * | 2011-12-07 | 2013-06-13 | 한국생명공학연구원 | Pharmaceutical composition for preventing and treating metabolic diseases, comprising nymphaea tetragona root extract, fractions thereof, or polyphenol-based compounds isolated from the nymphaea tetragona root extract as active ingredients |
Also Published As
Publication number | Publication date |
---|---|
CN109694394A (en) | 2019-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104341430B (en) | A kind of soil Radix Glycyrrhizae A and extracting method thereof and purposes | |
CN102526315B (en) | Preparation method of extracts of effective fractions of lychee seeds | |
CN102861112A (en) | Kosteletzkya virginica lignan extract and preparation method and application thereof | |
CN101607976A (en) | A kind of preparation method of icariin | |
CN103304613A (en) | Method for separating and purifying four nucleoside chemical ingredients from trichosanthes bark | |
CN102372754A (en) | Method for preparing specnuezhenide | |
CN109942649B (en) | Indole glycoside compound and extraction and separation method and application thereof | |
CN102335348A (en) | Gastrodia elata plant extract for preventing parkinson disease and preparation method thereof | |
CN101891727A (en) | Method for separating and extracting apigenin, locustin-7-O-β-D-glucoside and apigenin-7-O-β-D-glucoside from Shennong Xiangju | |
CN107556325B (en) | A kind of separation method of trace alkaloid monomers in blood loose potato | |
CN103565781B (en) | Composite, preparation thereof and application of composite in preparing antidepressant drug | |
CN111689965A (en) | Alkaloid compound with antitumor activity and preparation method and application thereof | |
CN101538297A (en) | Preparation method of high-purity monomer flavone and general flavone contained in capsella bursa-pastoris and application of general flavone | |
CN109694394B (en) | Preparation method and application of tannin extract in sea buckthorn | |
CN108689851A (en) | A kind of tigliane type diterpene compound and its preparation method and application | |
CN102772501A (en) | Rheum emodi Wall. extract and its preparing method | |
CN111647031B (en) | Alkaloid and extraction and separation method and application thereof | |
CN112194704B (en) | A kind of steroidal saponin compound and its preparation method and application | |
CN110251552B (en) | A kind of preparation method of total flavonoids of A. | |
CN111217873B (en) | Sesquiterpene glycoside monomer compound and preparation method and application thereof | |
CN106674299A (en) | Polyacetylenic glycoside compounds as well as preparation method and application thereof | |
CN110204589B (en) | Active ingredients, extraction method and application in the preparation of neuroprotective drugs | |
CN103113439A (en) | Method for preparing kaempferol-3-O-Beta-D-glucuronide in euphorbia sororia | |
CN103239435B (en) | Preparation method of gynura divaricata total caffeoylquinic acid and application in antihyperglycemic agent or health-care product | |
CN116375669B (en) | Monoterpene lactone compound, preparation method thereof and application thereof in preparation of anticomplement medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |